Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

PARIS, March 21 (Reuters) - Healthcare companies Sanofi and Regeneron announced on Tuesday that their Dupixent product, which treats the skin disease atopic dermatitis, had won a new regulatory ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Regeneron Pharmaceuticals Inc ... in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 Revolutionizing ...

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

The American Academy of Dermatology gratefully acknowledges the support from Sanofi and Regeneron. Atopic dermatitis, or eczema, is often called the “itch that rashes.” This description explains what ...